These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 19911397)

  • 1. R-roscovitine (Seliciclib) affects CLL cells more strongly than combinations of fludarabine or cladribine with cyclophosphamide: Inhibition of CDK7 sensitizes leukemic cells to caspase-dependent apoptosis.
    Rogalińska M; Błoński JZ; Komina O; Góralski P; Zołnierczyk JD; Piekarski H; Robak T; Kiliańska ZM; Wesierska-Gadek J
    J Cell Biochem; 2010 Jan; 109(1):217-35. PubMed ID: 19911397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roscovitine triggers apoptosis in B-cell chronic lymphocytic leukemia cells with similar efficiency as combinations of conventional purine analogs with cyclophosphamide.
    Zolnierczyk JD; Błoński JZ; Robak T; Kiliańska ZM; Wesierska-Gadek J
    Ann N Y Acad Sci; 2009 Aug; 1171():124-31. PubMed ID: 19723046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can ex vivo evaluation (testing) predict the sensitivity of CLL cells to therapy with purine analogs in conjunction with an alkylating agent? A comparison of in vivo and ex vivo responses to treatment.
    Żołnierczyk JD; Komina O; Błoński JZ; Borowiak A; Cebula-Obrzut B; Smolewski P; Robak P; Kiliańska ZM; Węsierska-Gądek J
    Med Oncol; 2012 Sep; 29(3):2111-26. PubMed ID: 22086735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo and ex vivo responses of CLL cells to purine analogs combined with alkylating agent.
    Żołnierczyk JD; Borowiak A; Błoński JZ; Cebula-Obrzut B; Rogalińska M; Kotkowska A; Wawrzyniak E; Smolewski P; Robak T; Kiliańska ZM
    Pharmacol Rep; 2013; 65(2):460-75. PubMed ID: 23744431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of NF-κB-mediated signaling by the cyclin-dependent kinase inhibitor CR8 overcomes prosurvival stimuli to induce apoptosis in chronic lymphocytic leukemia cells.
    Cosimo E; McCaig AM; Carter-Brzezinski LJ; Wheadon H; Leach MT; Le Ster K; Berthou C; Durieu E; Oumata N; Galons H; Meijer L; Michie AM
    Clin Cancer Res; 2013 May; 19(9):2393-405. PubMed ID: 23532892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells.
    Hahntow IN; Schneller F; Oelsner M; Weick K; Ringshausen I; Fend F; Peschel C; Decker T
    Leukemia; 2004 Apr; 18(4):747-55. PubMed ID: 14973497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between in vitro drug sensitivity and clinical response of patients to treatment in chronic lymphocytic leukemia.
    Rogalińska M; Błoński JZ; Góralski P; Wawrzyniak E; Hartman M; Rogalska A; Robak P; Koceva-Chyła A; Piekarski H; Robak T; Kiliańska ZM
    Int J Oncol; 2015 Mar; 46(3):1259-67. PubMed ID: 25572009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resveratrol increases rate of apoptosis caused by purine analogues in malignant lymphocytes of chronic lymphocytic leukemia.
    Podhorecka M; Halicka D; Klimek P; Kowal M; Chocholska S; Dmoszynska A
    Ann Hematol; 2011 Feb; 90(2):173-83. PubMed ID: 20714724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fludarabine-induced apoptosis of B chronic lymphocytic leukemia cells includes early cleavage of p27kip1 by caspases.
    Sanhes L; Tang R; Delmer A; DeCaprio JA; Ajchenbaum-Cymbalista F
    Leukemia; 2003 Jun; 17(6):1104-11. PubMed ID: 12764376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simvastatin and purine analogs have a synergic effect on apoptosis of chronic lymphocytic leukemia cells.
    Podhorecka M; Halicka D; Klimek P; Kowal M; Chocholska S; Dmoszynska A
    Ann Hematol; 2010 Nov; 89(11):1115-24. PubMed ID: 20499237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells.
    Battle TE; Arbiser J; Frank DA
    Blood; 2005 Jul; 106(2):690-7. PubMed ID: 15802533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia.
    Chen R; Wierda WG; Chubb S; Hawtin RE; Fox JA; Keating MJ; Gandhi V; Plunkett W
    Blood; 2009 May; 113(19):4637-45. PubMed ID: 19234140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid onset of nucleolar disintegration preceding cell cycle arrest in roscovitine-induced apoptosis of human MCF-7 breast cancer cells.
    Wojciechowski J; Horky M; Gueorguieva M; Węsierska-Gądek J
    Int J Cancer; 2003 Sep; 106(4):486-495. PubMed ID: 12845642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study).
    Robak T; Jamroziak K; Gora-Tybor J; Stella-Holowiecka B; Konopka L; Ceglarek B; Warzocha K; Seferynska I; Piszcz J; Calbecka M; Kostyra A; Dwilewicz-Trojaczek J; Dmoszyñska A; Zawilska K; Hellmann A; Zdunczyk A; Potoczek S; Piotrowska M; Lewandowski K; Blonski JZ
    J Clin Oncol; 2010 Apr; 28(11):1863-9. PubMed ID: 20212251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival.
    Alvi AJ; Austen B; Weston VJ; Fegan C; MacCallum D; Gianella-Borradori A; Lane DP; Hubank M; Powell JE; Wei W; Taylor AM; Moss PA; Stankovic T
    Blood; 2005 Jun; 105(11):4484-91. PubMed ID: 15692065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
    Robak T; Lech-Maranda E; Robak P
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cytotoxic activity of Aplidin in chronic lymphocytic leukemia (CLL) is mediated by a direct effect on leukemic cells and an indirect effect on monocyte-derived cells.
    Morande PE; Zanetti SR; Borge M; Nannini P; Jancic C; Bezares RF; Bitsmans A; González M; Rodríguez AL; Galmarini CM; Gamberale R; Giordano M
    Invest New Drugs; 2012 Oct; 30(5):1830-40. PubMed ID: 21887502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Roscovitine, a selective CDK inhibitor, reduces the basal and estrogen-induced phosphorylation of ER-α in human ER-positive breast cancer cells.
    Węsierska-Gądek J; Gritsch D; Zulehner N; Komina O; Maurer M
    J Cell Biochem; 2011 Mar; 112(3):761-72. PubMed ID: 21328450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia.
    Bosanquet AG; Sturm I; Wieder T; Essmann F; Bosanquet MI; Head DJ; Dörken B; Daniel PT
    Leukemia; 2002 Jun; 16(6):1035-44. PubMed ID: 12040435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DHMEQ, a new NF-kappaB inhibitor, induces apoptosis and enhances fludarabine effects on chronic lymphocytic leukemia cells.
    Horie R; Watanabe M; Okamura T; Taira M; Shoda M; Motoji T; Utsunomiya A; Watanabe T; Higashihara M; Umezawa K
    Leukemia; 2006 May; 20(5):800-6. PubMed ID: 16525497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.